Drug delivery

Dr Jason Bellia, Senior Patent Examiner at the UK Intellectual Property Office (IPO) I will look at just two of a vast number of routes - one to deliver nucleic acids across cell membranes and another looking...

The SPC manufacturing waiver: curtailing protection or boosting competition?

Lucy O’Brien, Trainee Patent Attorney, A. A. Thornton & Co. Supplementary Protection Certificates (SPCs) are a valuable IP asset to most major life science businesses. The ability to extend the term of a patent relating to a...

How to protect your IP rights in Europe

Intellectual property rights are territorial rights, meaning that the protection afforded by a granted patent or a registered trademark is geographically limited. Many companies that protect their inventions, brands or product designs in their home...

Compulsory licensing of pharmaceuticals: A solution to high drug prices?

The UK continues to grapple with its departure – or not – from the European Union, and whilst the outcome remains unclear, one thing now seems certain: before long there will be a general...

Plant patentability and the European Patent Office – what is the latest update?

Plant patentability has long been a contentious issue throughout intellectual property and scientific circles. The question as to whether plants or animals created through essentially biological processes, such as genetic or selective breeding, can be...

Biosimilars and Patents

Leonita Paulraj - Associate, AA Thornton The majority of the world’s biggest selling medicines can be classified as “biologics” or “biopharmaceuticals”. Such medicines contain one or more biologically active product produced from (or containing components of)...

UK Supreme Court inflicts more patent pain on Warner-Lambert

Eilidh Pugh, Pharmaceutical Patent Attorney, AdamsonJones. The UK Supreme Court has handed down its much-anticipated decision in WarnerLambert Company LLC v Generics (UK) Ltd t/a Mylan and Actavis. The case is important because it is the...

Patent Protection of Medical Devices – Time for a Rethink?

Christopher Burnett,  Patent Attorney,  AA Thornton The duration of patent protection for medical devices is up to twenty years, as for any other type of device. Pharmaceuticals, on the other hand, may be entitled to an...

How intellectual property can help 3D printing support, not harm, medtech

3D printing, or additive manufacturing, is frequently, and rightly, hailed as the next revolution in technology. Since its inception in 1986, 3D printing has transformed numerous sectors including aviation, manufacturing, and energy, and altered perceptions...

Considering a pharma and bioscience patent? The UK Intellectual Property Office maps out the...

Lawrence Cullen & Laura Starrs, Patent Examining Group Heads, IPO Managing a patent portfolio requires, among many skills, the ability to anticipate the future. This is especially true in the fields of bioscience and pharma where,...

Patenting aerospace medicines – the final frontier?

Research and development (R&D) into aerospace medicine can be viewed as falling into one of two camps: that aimed at adapting an existing ‘terrestrial’ medicine for use in the aerospace environment; and that which...

Know your third party patent rights

In the competitive world of the biosciences, third party patent rights (TPRs) can stand in the way of a planned course of action, even after significant investment has been made. Knowledge of such rights...

The IP journey and risk mitigation

Paul Storer Senior Policy Adviser in the Business Support Policy Team at the IPO Resolving IP disputes can be costly and the Intellectual Property Office continues to seek to reduce costs for businesses, not only in...

Preparations for AI patenting in Europe

The current era of rapid technological development requires industry to be quick to respond to challenges and opportunities, with many choosing to exploit new AI technologies rather than wait to be disrupted by competitors. Intellectual...

EU-wide IP Expertise is essential to the life science industry post-Brexit

The UK is world-renowned for its progressive life science and healthcare sectors, which are at the forefront of technical innovation, research excellence, and pioneering treatments. Life science companies, research and development facilities, scientists and academics...

The importance of Intellectual Property strategy; creating a foundation on which to build value...

Dr Emma Longland and Craig Thomson of HGF writing for the Chartered Institute of Patent Attorneys Most companies in the Biotech space appreciate the need for patent protection; after all, no company wants to bring...